Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis
CONCLUSIONS: The comparative effects of different ESAs on blood transfusions, death (any cause and cardiovascular), major cardiovascular events, myocardial infarction, stroke, vascular access thrombosis, kidney failure, fatigue and breathlessness were uncertain.PMID:36791280 | PMC:PMC9924302 | DOI:10.1002/14651858.CD010590.pub3 (Source: Cochrane Database of Systematic Reviews)
Source: Cochrane Database of Systematic Reviews - February 15, 2023 Category: General Medicine Authors: Edmund Ym Chung Suetonia C Palmer Valeria M Saglimbene Jonathan C Craig Marcello Tonelli Giovanni Fm Strippoli Source Type: research
Erythropoiesis-stimulating agents for anaemia in adults with chronic kidney disease: a network meta-analysis
CONCLUSIONS: The comparative effects of different ESAs on blood transfusions, death (any cause and cardiovascular), major cardiovascular events, myocardial infarction, stroke, vascular access thrombosis, kidney failure, fatigue and breathlessness were uncertain.PMID:36791280 | DOI:10.1002/14651858.CD010590.pub3 (Source: Cochrane Database of Systematic Reviews)
Source: Cochrane Database of Systematic Reviews - February 15, 2023 Category: General Medicine Authors: Edmund Ym Chung Suetonia C Palmer Valeria M Saglimbene Jonathan C Craig Marcello Tonelli Giovanni Fm Strippoli Source Type: research
Efficacy and safety of vadadustat compared to darbepoetin alfa on anemia in patients with chronic kidney disease: a meta-analysis
ConclusionCompared to darbepoetin alfa, vadadustat had the same effect in raising the hemoglobin level in NDD-CKD patients in the short term. Vadadustat may become an effective and safe alternative for the treatment of patients with anemia and CKD, especially in NDD-CKD patients. As the application of vadadustat is still under exploration, future research should compensate for the limitations of our study to estimate the vadadustat’s value. (Source: International Urology and Nephrology)
Source: International Urology and Nephrology - January 22, 2023 Category: Urology & Nephrology Source Type: research
Darbepoetin Alfa for Late-onset Anemia in Neonates with Rhesus Hemolytic Disease
AbstractNeonates with Rhesus hemolytic disease can present with anemia beyond 1 wk of age due to bone marrow suppression and low erythropoietin secretion. Erythropoietin stimulating agents (ESA) were tried to manage anemia in these neonates. Darbepoetin alfa (DA) is a long-acting ESA used to treat anemia in premature neonates and in children with chronic kidney disease or on cancer chemotherapy. The authors present their experience of using DA to treat late-onset hyporegenerative anemia in 3 neonates with Rhesus isoimmunization. Darbepoetin alfa 4 mcg/kg was given subcutaneously at a 1 –2-wk interval to target hemoglobin...
Source: Indian Journal of Pediatrics - December 3, 2022 Category: Pediatrics Source Type: research
Overall Adverse Event Profile of Vadadustat for the Treatment of Anemia Associated With Chronic Kidney Disease in Phase 3 Trials
Conclusion: Among patients with CKD-related anemia treated with vadadustat, we observed similar rates of adverse events relative to those treated with darbepoetin alfa. (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - November 30, 2022 Category: Neurology Source Type: research
Overall Adverse Event Profile of Vadadustat for the Treatment of Anemia Associated With Chronic Kidney Disease in Phase 3 Trials
CONCLUSION: Among patients with CKD-related anemia treated with vadadustat, we observed similar rates of adverse events relative to those treated with darbepoetin alfa.PMID:36450264 | DOI:10.1159/000528443 (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - November 30, 2022 Category: Urology & Nephrology Authors: Rajiv Agarwal Sanjeev Anand Kai-Uwe Eckardt Wenli Luo Patrick S Parfrey Mark J Sarnak Christine M Solinsky Dennis L Vargo Wolfgang C Winkelmayer Glenn M Chertow Source Type: research
Four Cases of Serum Copper Excess in Patients with Renal Anemia Receiving a Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor: A Possible Safety Concern
Copper is an indispensable trace metal element and is mainly absorbed in the stomach and small intestine and excreted into the bile. Hypoxia-inducible factor-prolyl hydroxylase inhibitors (HIF-PHIs) have emerged as a novel approach for renal anemia management. Many intestinal genes, includingdivalent metal transporter 1,duodenal cytochrome B, and copper transporter ATPase7A, related to iron absorption are transactivated by HlF- α, during iron deficiency. We first report 4 cases of patients with renal anemia who showed excess in serum copper level during roxadustat or daprodustat treatment, which were decreased to the norm...
Source: Case Reports in Nephrology and Dialysis - August 19, 2022 Category: Urology & Nephrology Source Type: research
ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial
This study indicated that anemic patients who have higher erythropoietin levels and harbor ASXL1 gene mutations may respond poorly to DA. Alternative strategies are needed for the treatment of anemia in this population. Trial registration number and date of registration: UMIN000022185 and 09/05/2016.PMID:35821550 | DOI:10.1007/s12185-022-03414-9 (Source: International Journal of Hematology)
Source: International Journal of Hematology - July 13, 2022 Category: Hematology Authors: Yasuyoshi Morita Yasuhito Nannya Motoshi Ichikawa Hitoshi Hanamoto Hirohiko Shibayama Yoshinobu Maeda Tomoko Hata Toshihiro Miyamoto Hiroshi Kawabata Kazuto Takeuchi Hiroko Tanaka Junji Kishimoto Satoru Miyano Itaru Matsumura Seishi Ogawa Koichi Akashi Yu Source Type: research
ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial
This study indicated that anemic patients who have higher erythropoietin levels and harbor ASXL1 gene mutations may respond poorly to DA. Alternative strategies are needed for the treatment of anemia in this population. Trial registration number and date of registration: UMIN000022185 and 09/05/2016.PMID:35821550 | DOI:10.1007/s12185-022-03414-9 (Source: International Journal of Hematology)
Source: International Journal of Hematology - July 13, 2022 Category: Hematology Authors: Yasuyoshi Morita Yasuhito Nannya Motoshi Ichikawa Hitoshi Hanamoto Hirohiko Shibayama Yoshinobu Maeda Tomoko Hata Toshihiro Miyamoto Hiroshi Kawabata Kazuto Takeuchi Hiroko Tanaka Junji Kishimoto Satoru Miyano Itaru Matsumura Seishi Ogawa Koichi Akashi Yu Source Type: research
ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial
This study indicated that anemic patients who have higher erythropoietin levels and harbor ASXL1 gene mutations may respond poorly to DA. Alternative strategies are needed for the treatment of anemia in this population. Trial registration number and date of registration: UMIN000022185 and 09/05/2016.PMID:35821550 | DOI:10.1007/s12185-022-03414-9 (Source: International Journal of Hematology)
Source: International Journal of Hematology - July 13, 2022 Category: Hematology Authors: Yasuyoshi Morita Yasuhito Nannya Motoshi Ichikawa Hitoshi Hanamoto Hirohiko Shibayama Yoshinobu Maeda Tomoko Hata Toshihiro Miyamoto Hiroshi Kawabata Kazuto Takeuchi Hiroko Tanaka Junji Kishimoto Satoru Miyano Itaru Matsumura Seishi Ogawa Koichi Akashi Yu Source Type: research
Regulation of Erythropoiesis by the Hypoxia-Inducible Factor Pathway: Effects of Genetic and Pharmacological Perturbations
Annu Rev Med. 2022 Jun 30. doi: 10.1146/annurev-med-042921-102602. Online ahead of print.ABSTRACTRed blood cells transport O2 from the lungs to body tissues. Hypoxia stimulates kidney cells to secrete erythropoietin (EPO), which increases red cell mass. Hypoxia-inducible factors (HIFs) mediate EPO gene transcriptional activation. HIF-α subunits are subject to O2-dependent prolyl hydroxylation and then bound by the von Hippel-Lindau protein (VHL), which triggers their ubiquitination and proteasomal degradation. Mutations in the genes encoding EPO, EPO receptor, HIF-2α, prolyl hydroxylase domain protein 2 (PHD2), or VHL ca...
Source: Annual Review of Medicine - June 30, 2022 Category: General Medicine Authors: Gregg L Semenza Source Type: research
Regulation of Erythropoiesis by the Hypoxia-Inducible Factor Pathway: Effects of Genetic and Pharmacological Perturbations
Annu Rev Med. 2022 Jun 30. doi: 10.1146/annurev-med-042921-102602. Online ahead of print.ABSTRACTRed blood cells transport O2 from the lungs to body tissues. Hypoxia stimulates kidney cells to secrete erythropoietin (EPO), which increases red cell mass. Hypoxia-inducible factors (HIFs) mediate EPO gene transcriptional activation. HIF-α subunits are subject to O2-dependent prolyl hydroxylation and then bound by the von Hippel-Lindau protein (VHL), which triggers their ubiquitination and proteasomal degradation. Mutations in the genes encoding EPO, EPO receptor, HIF-2α, prolyl hydroxylase domain protein 2 (PHD2), or VHL ca...
Source: Annual Review of Medicine - June 30, 2022 Category: General Medicine Authors: Gregg L Semenza Source Type: research
Regulation of Erythropoiesis by the Hypoxia-Inducible Factor Pathway: Effects of Genetic and Pharmacological Perturbations
Annu Rev Med. 2022 Jun 30. doi: 10.1146/annurev-med-042921-102602. Online ahead of print.ABSTRACTRed blood cells transport O2 from the lungs to body tissues. Hypoxia stimulates kidney cells to secrete erythropoietin (EPO), which increases red cell mass. Hypoxia-inducible factors (HIFs) mediate EPO gene transcriptional activation. HIF-α subunits are subject to O2-dependent prolyl hydroxylation and then bound by the von Hippel-Lindau protein (VHL), which triggers their ubiquitination and proteasomal degradation. Mutations in the genes encoding EPO, EPO receptor, HIF-2α, prolyl hydroxylase domain protein 2 (PHD2), or VHL ca...
Source: Annual Review of Medicine - June 30, 2022 Category: General Medicine Authors: Gregg L Semenza Source Type: research
Regulation of Erythropoiesis by the Hypoxia-Inducible Factor Pathway: Effects of Genetic and Pharmacological Perturbations
Annu Rev Med. 2022 Jun 30. doi: 10.1146/annurev-med-042921-102602. Online ahead of print.ABSTRACTRed blood cells transport O2 from the lungs to body tissues. Hypoxia stimulates kidney cells to secrete erythropoietin (EPO), which increases red cell mass. Hypoxia-inducible factors (HIFs) mediate EPO gene transcriptional activation. HIF-α subunits are subject to O2-dependent prolyl hydroxylation and then bound by the von Hippel-Lindau protein (VHL), which triggers their ubiquitination and proteasomal degradation. Mutations in the genes encoding EPO, EPO receptor, HIF-2α, prolyl hydroxylase domain protein 2 (PHD2), or VHL ca...
Source: Annual Review of Medicine - June 30, 2022 Category: General Medicine Authors: Gregg L Semenza Source Type: research
Regulation of Erythropoiesis by the Hypoxia-Inducible Factor Pathway: Effects of Genetic and Pharmacological Perturbations
Annu Rev Med. 2022 Jun 30. doi: 10.1146/annurev-med-042921-102602. Online ahead of print.ABSTRACTRed blood cells transport O2 from the lungs to body tissues. Hypoxia stimulates kidney cells to secrete erythropoietin (EPO), which increases red cell mass. Hypoxia-inducible factors (HIFs) mediate EPO gene transcriptional activation. HIF-α subunits are subject to O2-dependent prolyl hydroxylation and then bound by the von Hippel-Lindau protein (VHL), which triggers their ubiquitination and proteasomal degradation. Mutations in the genes encoding EPO, EPO receptor, HIF-2α, prolyl hydroxylase domain protein 2 (PHD2), or VHL ca...
Source: Annual Review of Medicine - June 30, 2022 Category: General Medicine Authors: Gregg L Semenza Source Type: research
